Overview

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Status:
Recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in patients with locally-advanced anal squamous cell carcinoma (ASCC).

Phase:

Phase 2

Details

Lead Sponsor:

Goethe University

Treatments:

Antibodies, Monoclonal
Durvalumab
Fluorouracil
Immune Checkpoint Inhibitors
Mitomycin
Mitomycins